Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: The New EPOC randomised controlled trial

The Lancet Oncology

Volumn 15, Issue 6, 2014, Pages 601-611

  Primrose, John ^a   Falk, Stephen ^b   Finch Jones, Meg ^b   Valle, Juan ^c,d   O'Reilly, Derek ^e   Siriwardena, Ajith ^f   Hornbuckle, Joanne ^g   Peterson, Mark ^g   Rees, Myrddin ^h   Iveson, Tim ⁱ   Hickish, Tamas ^j   Butler, Rachel ^k   Stanton, Louise ^l   Dixon, Elizabeth ^l   Little, Louisa ^l   Bowers, Megan ^l   Pugh, Siân ^a   Garden, O James ^m   Cunningham, David ⁿ   Maughan, Tim ^o   Bridgewater, John ^p   more..

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d CHRISTIE HOSPITAL   (United Kingdom)

^e NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

^f MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^g SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^h BASINGSTOKE AND NORTH HAMPSHIRE HOSPITAL   (United Kingdom)

ⁱ UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^j ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

^k UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^l UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^m UNIVERSITY OF EDINBURGH   (United Kingdom)

ⁿ INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^o UNIVERSITY OF OXFORD   (United Kingdom)

^p UNIVERSITY COLLEGE LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CETUXIMAB; FLUOROURACIL; IRINOTECAN; OXALIPLATIN;

ABDOMINAL PAIN; ACUTE CONFUSION; ACUTE KIDNEY FAILURE; ADJUVANT THERAPY; ADULT; AGED; ALLERGIC REACTION; ALOPECIA; ANAPHYLAXIS; ARTICLE; BRONCHOPNEUMONIA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; COLORECTAL LIVER METASTASIS; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG DOSE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; EMBOLISM; EXON; FEBRILE NEUTROPENIA; FEMALE; HEART ARREST; HEART FAILURE; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; INFECTION; INTERSTITIAL LUNG DISEASE; LARYNX SPASM; LETHARGY; LIVER DISEASE; LIVER HEMORRHAGE; LOADING DRUG DOSE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; ONCOGENE K RAS; PAIN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; RIGOR; SEPSIS; STOMACH OBSTRUCTION; STOMATITIS; SYSTEMIC THERAPY; THORAX PAIN; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR DIFFERENTIATION; VEIN PAIN; VISUAL DISORDER; VOMITING; WILD TYPE;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; PROPORTIONAL HAZARDS MODELS; TREATMENT OUTCOME;

EID: 84899900161     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70105-6     Document Type: Article

References (37)

1. Bismuth H, Adam R, Levi F, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996, 224:509-520.
2. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004, 240:644-657.
3. Kanas GP, Taylor A, Primrose JN, et al. Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clin Epidemiol 2012, 4:283-301.
4. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008, 371:1007-1016.
5. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 2013, 14:1208-1215.
6. Folprecht G, Gruenberger T, Bechstein WO, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010, 11:38-47.
7. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008, 359:1757-1765.
8. Tabernero J, Van Cutsem E, Diaz-Rubio E, et al. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2007, 25:5225-5232.
9. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004, 351:337-345.
10. Peeters M, Price TJ, Cervantes A, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010, 28:4706-4713.
11. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009, 27:663-671.
12. Sobrero AF, Maurel J, Fehrenbacher L, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:2311-2319.
13. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009, 360:1408-1417.
14. Maughan TS, Adams RA, Smith CG, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011, 377:2103-2114.
15. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:1626-1634.
16. Adams RA, Meade AM, Madi A, et al. Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience. Br J Cancer 2009, 100:251-258.
17. Madi A, Fisher D, Wilson RH, et al. Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial. Br J Cancer 2012, 107:1037-1043.
18. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
19. Freidlin B, Korn EL, Gray R A general inefficacy interim monitoring rule for randomized clinical trials. Clin Trials 2010, 7:197-208.
20. Waddell T, Chau I, Cunningham D, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol 2013, 14:481-489.
21. Crosby T, Hurt CN, Falk S, et al. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. Lancet Oncol 2013, 14:627-637.
22. Douillard JY, Oliner KS, Siena S, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013, 369:1023-1034.
23. Tveit KM, Guren T, Glimelius B, et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol 2012, 30:1755-1762.
24. Welsh FK, Tilney HS, Tekkis PP, John TG, Rees M Safe liver resection following chemotherapy for colorectal metastases is a matter of timing. Br J Cancer 2007, 96:1037-1042.
25. Dahan L, Sadok A, Formento JL, Seitz JF, Kovacic H Modulation of cellular redox state underlies antagonism between oxaliplatin and cetuximab in human colorectal cancer cell lines. Br J Pharmacol 2009, 158:610-620.
26. Van Cutsem E, Tejpar S, Vanbeckevoort D, et al. Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study. J Clin Oncol 2012, 30:2861-2868.
27. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007, 25:1658-1664.
28. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007, 357:2040-2048.
29. Van Cutsem E, Kohne CH, Lang I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011, 29:2011-2019.
30. Alberts SR, Sargent DJ, Nair S, et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA 2012, 307:1383-1393.
31. Taïeb J, Tabernero J, Mini E, et al. Subgroup analyses results of the PETACC8 phase III trial comparing adjuvant FOLFOX4 with or without cetuximab in resected stage III colon cancer. Ann Oncol 2013, 31(suppl):3525. (abstr).
32. Roth AD, Delorenzi M, Tejpar S, et al. Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer. J Natl Cancer Inst 2012, 104:1635-1646.
33. Seymour MT, Brown SR, Middleton G, et al. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol 2013, 14:749-759.
34. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
35. Yano S, Wang W, Li Q, et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res 2008, 68:9479-9487.
36. Liska D, Chen CT, Bachleitner-Hofmann T, Christensen JG, Weiser MR HGF rescues colorectal cancer cells from EGFR inhibition via MET activation. Clin Cancer Res 2011, 17:472-482.
37. Bardelli A, Corso S, Bertotti A, et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov 2013, 3:658-673.